Cencora Management

Management criteria checks 2/4

Cencora's CEO is Bob Mauch, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is $7.70M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth €5.24M. The average tenure of the management team and the board of directors is 2.8 years and 9.5 years respectively.

Key information

Bob Mauch

Chief executive officer

US$7.7m

Total compensation

CEO salary percentage	12.7%
CEO tenure	2.1yrs
CEO ownership	0.01%
Management average tenure	2.8yrs
Board average tenure	9.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bob Mauch's remuneration changed compared to Cencora's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	US$2b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	n/a	n/a	US$2b
Sep 30 2023	US$8m	US$975k	US$2b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$2b
Sep 30 2022	US$6m	US$850k	US$2b
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$6m	US$800k	US$2b
Jun 30 2021	n/a	n/a	-US$4b
Mar 31 2021	n/a	n/a	-US$4b
Dec 31 2020	n/a	n/a	-US$3b
Sep 30 2020	US$4m	US$700k	-US$3b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	n/a	n/a	US$649m
Sep 30 2019	US$4m	US$675k	US$855m
Jun 30 2019	n/a	n/a	US$956m
Mar 31 2019	n/a	n/a	US$930m
Dec 31 2018	n/a	n/a	US$1b
Sep 30 2018	US$3m	US$675k	US$2b

Compensation vs Market: Bob's total compensation ($USD7.70M) is above average for companies of similar size in the German market ($USD5.20M).

Compensation vs Earnings: Bob's compensation has increased by more than 20% in the past year.

CEO

Bob Mauch (57 yo)

2.1yrs

Tenure

US$7,697,850

Compensation

Dr. Robert P. Mauch, PharmD, Ph D., also known as Bob, is an Executive Vice President at Cencora, Inc. (formerly known as AmerisourceBergen Corporation) since February 2015 and served as its Group Presiden...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.15% € 61.2m
Robert Mauch	President	2.1yrs	US$7.70m	0.012% € 5.2m
James Cleary	Executive VP & CFO	6yrs	US$5.45m	0.058% € 24.5m
Elizabeth Campbell	Executive VP & Chief Legal Officer	3.2yrs	US$4.03m	0.0042% € 1.8m
Lazarus Krikorian	Senior VP	12.8yrs	no data	0.010% € 4.3m
Bennett Murphy	Senior Vice President of Investor Relations	no data	no data	no data
Jennifer Dubas	Senior VP & Chief Compliance Officer	no data	no data	no data
Silvana Battaglia	Executive VP & Chief Human Resources Officer	5.8yrs	US$3.48m	0.0056% € 2.4m
Richard Tremonte	EVP & President of U.S. Pharmaceuticals	less than a year	no data	no data
Ann Anaya	Senior VP and Chief Diversity Equity & Inclusion Officer	2.8yrs	no data	no data
Juan Guerra	EVP & President of International Business Group	less than a year	no data	no data
J. Quinn	VP & Corporate Treasurer	no data	no data	no data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Management: ABG's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Steven Collis	Executive Chairman	13.5yrs	US$17.51m	0.15% € 61.2m
Robert Mauch	President	less than a year	US$7.70m	0.012% € 5.2m
Lauren Tyler	Independent Director	1.1yrs	no data	no data
Richard Gochnauer	Independent Director	16.2yrs	US$300.10k	0.011% € 4.8m
Mark M. Durcan	Lead Independent Director	9.2yrs	US$380.05k	0.010% € 4.2m
Lon Greenberg	Independent Director	11.5yrs	US$332.60k	0.0057% € 2.4m
Kathleen Hyle	Independent Director	14.5yrs	US$320.10k	0.011% € 4.5m
Dennis Nally	Independent Director	4.8yrs	US$375.36k	0.0044% € 1.9m
Ornella Barra	Director	9.8yrs	no data	no data
Henry McGee	Independent Director	20yrs	US$320.10k	0.0077% € 3.2m
Lorence Kim	Independent director	2.1yrs	US$397.33k	0.000090% € 37.9k
Redonda Miller	Independent Director	1.8yrs	US$311.82k	0.00080% € 336.6k

9.5yrs

Average Tenure

64yo

Average Age

Experienced Board: ABG's board of directors are considered experienced (9.5 years average tenure).

Cencora Management

Management criteria checks 2/4

Key information

Recent management updates

Cencora, Inc. Announces Management Appointments

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Chairman recently sold €8.1m worth of stock

Recent updates

Cencora, Inc. Announces Management Appointments

Cencora, Inc. to Report Q4, 2024 Results on Nov 06, 2024

Cencora, Inc. Elects Frank Clyburn as New Independent Director, Effective October 1, 2024

Third quarter dividend of US$0.51 announced

Third quarter 2024 earnings released: EPS: US$2.44 (vs US$2.37 in 3Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend, Payable on August 26, 2024

Cencora, Inc. to Report Q3, 2024 Results on Jul 31, 2024

Second quarter dividend of US$0.51 announced

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on May 24, 2024

Second quarter 2024 earnings released: EPS: US$2.11 (vs US$2.15 in 2Q 2023)

Cencora, Inc. (NYSE:COR) announces an Equity Buyback for $2,000 million worth of its shares.

Cencora, Inc. to Report Q2, 2024 Results on May 01, 2024

Cencora, Inc. Reaffirms Guidance for Year 2024

Cencora, Inc. Announces CEO Changes, Effective October 1, 2024

Cencora’s FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products

First quarter dividend of US$0.51 announced

First quarter 2024 earnings released: EPS: US$3.01 (vs US$2.35 in 1Q 2023)

Cencora, Inc. Declares Quarterly Cash Dividend on Common Share, Payable on February 26, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc., Annual General Meeting, Mar 12, 2024

Cencora, Inc. to Report Q1, 2024 Results on Jan 31, 2024

Now 20% undervalued

Chairman recently sold €8.1m worth of stock

Insider recently sold €1.8m worth of stock

Cencora, Inc. Declares Quarterly Dividend, Payable November 27, 2023

Full year 2023 earnings released: EPS: US$8.62 (vs US$8.15 in FY 2022)

Cencora, Inc. to Report Q4, 2023 Results on Nov 02, 2023

Amerisourcebergen Corporation Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Third quarter 2023 earnings released: EPS: US$2.37 (vs US$1.95 in 3Q 2022)

AmerisourceBergen Corporation Declares Quarterly Cash Dividend, Payable on August 28, 2023

AmerisourceBergen Corporation to Report Q3, 2023 Results on Aug 02, 2023

TPG Inc. (NasdaqGS:TPG), AmerisourceBergen Corporation (NYSE:ABC) and the management team of OneOncology, Inc. acquired OneOncology, LLC from General Atlantic Service Company, L.P. and others.

Executive VP & Chief Legal Officer recently sold €675k worth of stock

Second quarter 2023 earnings released: EPS: US$2.15 (vs US$2.62 in 2Q 2022)

Insider recently sold €282k worth of stock

Senior VP recently sold €832k worth of stock

First quarter 2023 earnings released: EPS: US$2.35 (vs US$2.15 in 1Q 2022)

An unknown buyer acquired Brazil specialty business from AmerisourceBergen Corporation (NYSE:ABC).

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation, Annual General Meeting, Mar 09, 2023

AmerisourceBergen Corporation to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold €129k worth of stock

Executive VP & Chief Strategy Officer recently sold €475k worth of stock

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Elects Redonda Miller to Its Board of Directors, Effective January 1, 2023

AmerisourceBergen Corporation has completed a Follow-on Equity Offering in the amount of $1.546 billion.

Full year 2022 earnings released: EPS: US$8.15 (vs US$7.48 in FY 2021)

AmerisourceBergen Corporation Appoints Robert P. Mauch as Executive Vice President and Chief Operating Officer

AmerisourceBergen Corporation to Report Q4, 2022 Results on Nov 03, 2022

AmerisourceBergen Elects Lorence H. Kim, M.D., to Its Board of Directors

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh from AUCTUS Capital Partners AG for €1.3 billion.

AmerisourceBergen Corporation (NYSE:ABC) agreed to acquire Pharmalex Holding Gmbh for €1.28 billion.

Insufficient new directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age